These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 39420554)
21. Selection of Reference Regions to Model Neurodegeneration in Huntington Disease by 18F-FDG PET/CT Using Imaging and Clinical Parameters. López Mora DA; Sampedro F; Camacho V; Fernández A; Fuentes F; Duch J; Pérez-Perez J; Martínez-Horta S; Marín-Lahoz J; Domènech A; Flotats A; Estorch M; Kulisevsky J; Carrió I Clin Nucl Med; 2019 Jan; 44(1):e1-e5. PubMed ID: 30325816 [TBL] [Abstract][Full Text] [Related]
22. Hybrid 2-[18F] FDG PET/MRI in premanifest Huntington's disease gene-expansion carriers: The significance of partial volume correction. Hellem MNN; Vinther-Jensen T; Anderberg L; Budtz-Jørgensen E; Hjermind LE; Larsen VA; Nielsen JE; Law I PLoS One; 2021; 16(6):e0252683. PubMed ID: 34115782 [TBL] [Abstract][Full Text] [Related]
23. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. Chen W; Silverman DH; Delaloye S; Czernin J; Kamdar N; Pope W; Satyamurthy N; Schiepers C; Cloughesy T J Nucl Med; 2006 Jun; 47(6):904-11. PubMed ID: 16741298 [TBL] [Abstract][Full Text] [Related]
24. Thalamic metabolism and symptom onset in preclinical Huntington's disease. Feigin A; Tang C; Ma Y; Mattis P; Zgaljardic D; Guttman M; Paulsen JS; Dhawan V; Eidelberg D Brain; 2007 Nov; 130(Pt 11):2858-67. PubMed ID: 17893097 [TBL] [Abstract][Full Text] [Related]
25. Levels of Synaptic Proteins in Brain and Neurofilament Light Chain in Cerebrospinal Fluid and Plasma of OVT73 Huntington's Disease Sheep Support a Prodromal Disease State. Sapp E; Boudi A; Reid SJ; Trombetta BA; Kivisäkk P; Taghian T; Arnold SE; Howland D; Gray-Edwards H; Kegel-Gleason KB; DiFiglia M J Huntingtons Dis; 2023; 12(3):201-213. PubMed ID: 37661892 [TBL] [Abstract][Full Text] [Related]
26. Normal caudate glucose metabolism in persons at risk for Huntington's disease. Young AB; Penney JB; Starosta-Rubinstein S; Markel D; Berent S; Rothley J; Betley A; Hichwa R Arch Neurol; 1987 Mar; 44(3):254-7. PubMed ID: 2950844 [TBL] [Abstract][Full Text] [Related]
27. Type 1 cannabinoid receptor mapping with [18F]MK-9470 PET in the rat brain after quinolinic acid lesion: a comparison to dopamine receptors and glucose metabolism. Casteels C; Martinez E; Bormans G; Camon L; de Vera N; Baekelandt V; Planas AM; Van Laere K Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2354-63. PubMed ID: 20680268 [TBL] [Abstract][Full Text] [Related]
28. Microglial activation in presymptomatic Huntington's disease gene carriers. Tai YF; Pavese N; Gerhard A; Tabrizi SJ; Barker RA; Brooks DJ; Piccini P Brain; 2007 Jul; 130(Pt 7):1759-66. PubMed ID: 17400599 [TBL] [Abstract][Full Text] [Related]
29. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293 [TBL] [Abstract][Full Text] [Related]
30. Positron emission tomography imaging of regional cerebral glucose metabolism. Alavi A; Dann R; Chawluk J; Alavi J; Kushner M; Reivich M Semin Nucl Med; 1986 Jan; 16(1):2-34. PubMed ID: 2935938 [TBL] [Abstract][Full Text] [Related]
31. Cortical atrophic-hypometabolic dissociation in the transition from premanifest to early-stage Huntington's disease. Sampedro F; Martínez-Horta S; Perez-Perez J; Horta-Barba A; Lopez-Mora DA; Camacho V; Fernández-León A; Gomez-Anson B; Carrió I; Kulisevsky J Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1111-1116. PubMed ID: 30627816 [TBL] [Abstract][Full Text] [Related]
32. Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging. Russell DS; Jennings DL; Barret O; Tamagnan GD; Carroll VM; Caillé F; Alagille D; Morley TJ; Papin C; Seibyl JP; Marek KL Neurology; 2016 Feb; 86(8):748-54. PubMed ID: 26802091 [TBL] [Abstract][Full Text] [Related]
33. Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease. Wang X; Sarkar A; Cicchetti F; Yu M; Zhu A; Jokivarsi K; Saint-Pierre M; Brownell AL J Neurol Sci; 2005 Apr; 231(1-2):57-66. PubMed ID: 15792822 [TBL] [Abstract][Full Text] [Related]
35. Neuroinflammation in Huntington's Disease: New Insights with Lois C; González I; Izquierdo-García D; Zürcher NR; Wilkens P; Loggia ML; Hooker JM; Rosas HD ACS Chem Neurosci; 2018 Nov; 9(11):2563-2571. PubMed ID: 29719953 [TBL] [Abstract][Full Text] [Related]
36. Structural and metabolic brain correlates of apathy in Huntington's disease. Martínez-Horta S; Perez-Perez J; Sampedro F; Pagonabarraga J; Horta-Barba A; Carceller-Sindreu M; Gomez-Anson B; Lozano-Martinez GA; Lopez-Mora DA; Camacho V; Fernández-León A; Carrió I; Kulisevsky J Mov Disord; 2018 Jul; 33(7):1151-1159. PubMed ID: 29676484 [TBL] [Abstract][Full Text] [Related]
37. Early Post-ischemic Brain Glucose Metabolism Is Dependent on Function of TLR2: a Study Using [ Bajorat R; Kurth J; Stenzel J; Vollmar B; Krause BJ; Reuter DA; Schuerholz T; Bergt S Mol Imaging Biol; 2022 Jun; 24(3):466-478. PubMed ID: 34779968 [TBL] [Abstract][Full Text] [Related]
38. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies. Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296 [TBL] [Abstract][Full Text] [Related]
39. Inconsistencies in histone acetylation patterns among different HD model systems and HD post-mortem brains. Narayan P; Reid S; Scotter EL; McGregor AL; Mehrabi NF; Singh-Bains MK; Glass M; Faull RLM; Snell RG; Dragunow M Neurobiol Dis; 2020 Dec; 146():105092. PubMed ID: 32979507 [TBL] [Abstract][Full Text] [Related]
40. Brain glucose utilization in childhood Huntington's disease studied with positron emission tomography (PET). De Volder A; Bol A; Michel C; Cogneau M; Evrard P; Lyon G; Goffinet AM Brain Dev; 1988; 10(1):47-50. PubMed ID: 2967038 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]